Tvardi Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 (Signal Transducer and Activator of Transcription 3). STAT3 is a key regulatory protein positioned at the intersection of critical signaling pathways that drive survival, immune evasion, chronic inflammation, and uncontrolled deposition in cancer and fibrosis-driven diseases. Tvardi's proprietary approach directly inhibits STAT3, which has historically been considered an undruggable target. The company's lead product candidate is TTI-101, a first-generation direct STAT3 inhibitor. Tvardi is also developing TTI-109, a next-generation phosphate prodrug designed to enhance delivery and improve tolerability.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing a pipeline of oral, small molecule STAT3 inhibitors (lead candidate TTI-101 and next-generation candidate TTI-109) to target inflammatory, proliferative, and fibrosis-driven diseases.
Expected impact: Aims to address significant unmet needs in oncology (HCC) and inflammatory/fibrotic diseases (NASH, systemic sclerosis).
Actively evaluating potential partnership opportunities and non-dilutive funding options (such as grants or collaborations) to support later-stage development, commercialization, and extension of the cash runway.
Expected impact: De-risking the clinical pipeline and securing long-term capital without diluting existing shareholders.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Reverse merger allowing privately held Tvardi Therapeutics to transition into a publicly traded company on the Nasdaq under the ticker symbol 'TVRD', combining the resources of science and capital.
Financial impact: Tvardi received approximately $23.8 million in net cash from Cara at closing, which augmented a concurrent $28.3 million private placement financing to extend the cash runway.